A press release was issued by Eli Lilly and Company in January 2024, wherein the introduction of LillyDirect was declared. In the United States, the platform serves as a digital healthcare resource for the management and assistance of patients afflicted with obesity, migraine, and diabetes. As per the announcement, LillyDirect provides an array of services encompassing medication delivery, support, and disease management. While the press release does mention several other features, it concentrates predominantly on the LillyDirect Pharmacy Solutions feature. The platform of the company facilitates user connections with a third-party online pharmacy fulfillment service via LillyDirect Pharmacy Solutions. The rationale for this element is to facilitate patients' consistent access to their prescribed medications, thereby enhancing medication adherence. A chronic disease management burden is exacerbated by the complexity of the American healthcare system. Their objective with LillyDirect is to alleviate a portion of these burdens by streamlining the patient experience in an effort to enhance outcomes. The pharmacy component of the platform, according to the company, will enable patients to acquire specific Lilly medications directly from the company, thereby eradicating the need for an intermediary and facilitating easier access to affordable solutions.
Abbott introduced its digital health application, FreeStyle LibreLink, in India in November 2023. Users of the FreeStyle Libre system can obtain glucose readings on their mobile devices without the need for a finger test using the mobile application. By utilizing near-field communication (NFC) technology, glucose data is transmitted from the sensor to the mobile application. It enables smartphone users to assist in the monitoring of eight-hour glucose history and real-time trend patterns in order to better manage food, insulin use, medication, and exercise. By utilizing the FreeStyle LibreLink application, individuals diagnosed with diabetes are able to access real-time glucose readings on their mobile devices and transmit this data to their physicians via LibreLinkUp and LibreView.
Wearable Devices
Handheld Devices
DevicesSmart Glucose Meters
Continuous Glucose Monitoring Systems
Smart Insulin Pumps/Closed Loop Systems & Smart Insulin Patches
Data Management Software and Platforms
Digital Diabetes Management AppsWeight & Diet Management Apps
Diabetes & Blood Glucose Tracking Apps
Services
Homecare
Hospitals & Specialty Diabetes Clinics
Academic & Research Institutes
Others
Americas
North America
US
Canada
South America
Europe
Western Europe
Germany
France
Italy
Spain
UK
Rest of Western Europe
Eastern Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
The Middle East & Africa
Middle East
Africa
In August 2023,
Entered a partnership with Agamatrix to integrate its blood glucose monitoring devices with the Dario diabetes management platform.
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â 2032: USD 87.7 Billion |
| Â Â CAGR | Â Â 20.1 % (2023-2032) |
| Â Â Base Year | Â Â 2021 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Type, Product and Service, End User And Region |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Abbott Laboratories, Agamatrix, Inc., Ascensia Diabetes Care Holdings Ag., B. Braun Melsungen AG, Dariohealth Corporation, Dexcom, Inc., F. Hoffmann-La Roche, Glooko, Inc., Insulet Corporation, Lifescan, Inc., Medtronic PLC, Tandem Diabetes Care, Inc., Tidepool, and others |
| Â Â Key Market Opportunities | Â Â Adopting new technology and the best treatment option from a developed country |
| Â Â Key Market Drivers | Â Â The growing prevalence of diabetes is the major driver for the market. |
Digital Diabetes Management Market Highlights:
Frequently Asked Questions (FAQ) :
The Type of devices included in the Digital Diabetes Management Market are Wearable Devices, Handheld Devices.
The market is expected to exhibit a strong 20.1% CAGR over the forecast period from 2023 to 2032.
The growing prevalence of diabetes is the major driver for the market.
North America is the leading regional market, followed by Europe.
Leading players in the digital diabetes management market include B. Braun Melsungen, Abbott, F. Hoffman-La Roche, Agamatrix Inc., and Glooko, among others.
The global digital diabetes management market was valued at more than USD 4.4 billion in 2017.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
